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Abstract
Background: Iron deficiency (ID) is a major public health burden in African children and accurate prevalence
estimates are important for effective nutritional interventions. However, ID may be incorrectly estimated in Africa
because most measures of iron status are altered by inflammation and infections such as malaria. Through the
current study, we have assessed different approaches to the prediction of iron status and estimated the burden of
ID in African children.
Methods: We assayed iron and inflammatory biomarkers in 4853 children aged 0–8 years from Kenya, Uganda, Burkina
Faso, South Africa, and The Gambia. We described iron status and its relationship with age, sex, inflammation, and
malaria parasitemia. We defined ID using the WHO guideline (ferritin < 12 μg/L or < 30 μg/L in the presence of
inflammation in children < 5 years old or < 15 μg/L in children ≥ 5 years old). We compared this with a recently
proposed gold standard, which uses regression-correction for ferritin levels based on the relationship between ferritin
levels, inflammatory markers, and malaria. We further investigated the utility of other iron biomarkers in predicting ID
using the inflammation and malaria regression-corrected estimate as a gold standard.
Results: The prevalence of ID was highest at 1 year of age and in male infants. Inflammation and malaria parasitemia
were associated with all iron biomarkers, although transferrin saturation was least affected. Overall prevalence of WHO-
defined ID was 34% compared to 52% using the inflammation and malaria regression-corrected estimate. This
unidentified burden of ID increased with age and was highest in countries with high prevalence of inflammation and
malaria, where up to a quarter of iron-deficient children were misclassified as iron replete. Transferrin saturation < 11%
most closely predicted the prevalence of ID according to the regression-correction gold standard.
Conclusions: The prevalence of ID is underestimated in African children when defined using the WHO guidelines,
especially in malaria-endemic populations, and the use of transferrin saturation may provide a more accurate approach.
Further research is needed to identify the most accurate measures for determining the prevalence of ID in sub-Saharan
Africa.
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Background
Iron deficiency (ID) is the commonest nutrient defi-
ciency affecting over 2 billion people worldwide and is
a major public health burden in African children [1, 2].
ID has been associated with impaired brain develop-
ment and long-term impairment of behavioral and
cognitive performance [3]. In sub-Saharan Africa, ID
anemia (IDA) is the leading cause of years lived with
disability (YLD) in 30 of the 46 countries [2]. However,
despite its detrimental effects on health, the true bur-
den of ID in African children remains largely unknown
because of the complex interactions of the biochemical
markers of ID with inflammation and infections includ-
ing malaria [4, 5].
Reliable and accurate estimation of the prevalence of
ID is essential in planning, monitoring, and targeting
effective interventions. The gold standard method for es-
timating iron status is to stain bone marrow aspirate for
iron, but this is invasive and impractical in population
surveys [6]. To define ID in areas with high burden of
infectious diseases, the World Health Organization
(WHO) recommends the use of low ferritin concentra-
tions (< 12 μg/L in children < 5 years or < 15 μg/L in
children ≥ 5 years), with an arbitrarily higher cut-off of
ferritin (< 30 μg/L) in children < 5 years with inflamma-
tion (defined as C-reactive protein (CRP) > 5 mg/L) [7,
8]. Ferritin reflects body iron stores and has standardized
laboratory assays and established cut-offs; however, its
synthesis is also highly upregulated by inflammatory
cytokines [9] and by malaria, even in the absence of
inflammation [10]. We therefore hypothesized that the
WHO definition of ID may underestimate the preva-
lence of ID in areas with high burdens of inflammation
and malaria.
A range of alternative markers of iron status have been
proposed to determine iron status, but these also have
limitations. Soluble transferrin receptor (sTfR) is only
mildly increased during the inflammatory response [11],
but its utility is complicated in African populations since
it is upregulated by malaria, even in asymptomatic
infection, and by hemolytic conditions such as sickle cell
disease, thalassemia, and glucose-6-phosphate dehydro-
genase (G6PD) deficiency. Moreover there are no stan-
dardized sTfR reference assays [12–14]. Other iron
biomarkers may also be confounded by the effects of in-
flammation or malaria [8]. Although hemoglobin defines
anemia, its usefulness in defining ID is limited due to its
low specificity since the causes of anemia are multifac-
torial and hemoglobin levels only decline in late-stage
deficiency [15]. Estimating iron status in African chil-
dren is therefore challenging, although a number of
approaches have been proposed to account for the
effects of inflammation and malaria, including using
higher ferritin cut-offs, or excluding individuals with
raised inflammatory markers [4]. A regression-
correction approach, which accounts for the linear
effects of inflammatory markers and/or malaria on iron
biomarkers, as proposed by the Biomarkers Reflecting
Inflammation and Nutritional Determinants of Anemia
(BRINDA) project, appears to reflect iron status more
accurately [10, 16].
In the current study, we have measured a wide range
of iron markers in 4853 African children and described
their relationship with age, sex, underweight, inflamma-
tion, and malaria parasitemia. We then utilized the
regression-correction approach proposed by BRINDA
[10, 16] to predict what the ferritin level would have
been in the absence of inflammation and malaria, and
then used these predicted values to estimate the preva-
lence of ID in African children. We then compared the
regression-corrected prevalence of ID to the prevalence
of WHO-defined ID. Finally, we assessed the diagnostic
utility of various iron markers in predicting ID using an
approach based on the BRINDA regression-correction
method as a gold standard.
Methods
Study population
This study included community-based cohorts from
Kenya, Uganda, Burkina Faso, South Africa, and The
Gambia.
Kilifi, Kenya
Participants were members of an ongoing rolling cohort
evaluating malaria immunity in children as described
elsewhere [17]. Within this cohort, children were
followed up to 8 years with weekly follow-ups and
annual cross-sectional surveys during which anthropom-
etry measurements and blood samples were taken. Iron
and inflammatory biomarkers as well as malaria parasit-
emia were measured from blood samples collected at a
single cross-sectional survey based on the availability of
plasma samples archived at − 80 °C.
Entebbe, Uganda
The Entebbe Mother and Baby Study is a prospective
birth cohort study that was originally designed as a
randomized, double-blind, placebo-controlled trial
(ISRCTN32849447) to determine whether anthel-
minthic treatment during pregnancy and early child-
hood was associated with differential response to
vaccination or incidence of infections such as pneumo-
nia, diarrhea, or malaria [18]. Blood samples were col-
lected at birth and at subsequent annual visits up to age
5 years. Anthropometry and iron/inflammatory bio-
markers were measured from a single annual visit based
on the availability of stored samples.
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Banfora, Burkina Faso
The VAC050 ME-TRAP malaria vaccine trial tested the
safety, immunogenicity, and efficacy of a viral-vectored
prime-boost liver-stage malaria vaccine in infants be-
tween the ages of six and 17 months living in the Ban-
fora region of Burkina Faso [19]. Anthropometry and
plasma samples were available from the infants at mul-
tiple time-points following receipt of the experimental
vaccine. Iron and inflammatory biomarkers were assayed
from samples collected at time-points close to 12
months of age based on another study looking at the
genetics of responses against vaccines delivered as part
of the Expanded Programme on Immunization (EPI).
Soweto, South Africa
Infants born in Chris Hani Baragwanath Hospital living
in Soweto, a non-malaria-endemic region in Johannes-
burg, South Africa, were recruited from vaccine trials
coordinated by the Respiratory and Meningeal Patho-
gens Unit (http://www.rmpru.com/) [20]. This study
used plasma samples collected at 12 months of age in in-
fants who had received all of their EPI vaccines up to
6 months of age. Anthropometry and hemoglobin con-
centrations were not measured in this cohort.
West Kiang, The Gambia
All children aged 2 to 6 years and living in the West
Kiang region of The Gambia were recruited during the
malaria season to assess the effects of genetic variants
on hemoglobin concentrations and iron status [21]. Iron
biomarkers, anthropometric measurements, and malaria
parasitemia data were measured at a cross-sectional sur-
vey at the start of a malaria season.
Laboratory procedures
The assayed biomarkers of iron (plasma ferritin, sTfR,
hepcidin, serum iron, transferrin, unsaturated iron-
binding capacity (UIBC), zinc protoporphyrin (ZPP), and
hemoglobin) and inflammation (CRP and α1-antichymo-
trypsin (ACT)) are shown in Additional file 1: Table S1.
UIBC, ACT, and ZPP were only measured in Gambian
children. The Gambian hepcidin values were harmo-
nized by converting to the old DRG hepcidin assay
values and then to the new highly sensitive DRG hepci-
din assay values [22]. In Uganda, hemoglobin concentra-
tions were adjusted for an altitude of > 1000m above sea
level (by subtracting 0.2 g/dL) [23]. Plasmodium falcip-
arum and other Plasmodium species were examined
using Giemsa-stained thick and thin blood smears. All
assays are based on single measurements per child.
Definitions
Inflammation was defined as CRP > 5mg/L or ACT > 0.6
g/L [8]. ID was defined using the WHO recommended
definition as either (i) plasma ferritin < 12 μg/L in the
absence of inflammation or < 30 μg/L in the presence of
inflammation in children < 5 years or (ii) plasma ferritin <
15 μg/L in children ≥ 5 years [7]. Body iron stores (BIS)
were calculated as proposed by Cook et al. as
− [log10((sTfR in mg/L × 1000)/ferritin in μg/L) − 2.8229]/
0.1207 [24]. Ferritin index, a marker of bone marrow iron
depletion, was calculated as sTfR in mg/L/log10(ferritin in
μg/L) [25]. Transferrin saturation (TSAT) was calculated
as (serum iron in μmol/L/transferrin in g/L) × 25.1) × 100
in Kenya and Burkina Faso or as (serum iron in μmol/L/
UIBC in μmol/L + serum iron in μmol/L) × 100 in The
Gambia [26]. Serum iron measurements for calculation of
TSAT were not available in Uganda and South Africa
because plasma samples were stored in ethylenediamine-
tetraacetic acid (EDTA), which chelates iron. Anemia was
defined as Hb < 11 g/dL in children aged < 5 years, or
hemoglobin < 11.5 g/dL in children ≥ 5 years, while IDA
was defined as the presence of both ID and anemia [27].
Malaria parasitemia was defined as microscopy confirmed
P. falciparum parasitemia at any density. Underweight
was defined as weight-for-age z-score < − 2 using the
WHO Growth Reference Standards [28].
Statistical analyses
All analyses were conducted using STATA 13.0 (Stata-
Corp., College Station, TX). Iron biomarkers (except
transferrin, hemoglobin and BIS) were ln-transformed to
normalize their distributions. Differences in biomarker
means between age groups were tested using two-tailed
Student’s t tests assuming unequal variance. We fitted
univariable and multivariable linear regression models to
determine the associations between iron biomarkers and
age, sex, underweight, inflammation, and malaria para-
sitemia. Where analyses were pooled, Gambian sTfR,
TSAT, BIS, and ferritin index were excluded since differ-
ent assays were used in this population meaning that
values were not directly comparable with those from
other cohorts (Additional file 1: Table S1). All p values
reflect two-tailed tests and a p value of < 0.05 was con-
sidered significant.
Regression correction
Following analyses of predictors of iron status, we then
aimed to estimate the prevalence of ID by adjusting for
the effects of inflammation and malaria on ferritin levels
using a regression-correction approach as developed by
BRINDA [10, 16]. We used these estimates as our gold
standard. The regression-correction approach followed a
three-step process. In the first step, internal reference
values for inflammatory markers (CRP or ACT) were de-
fined as the 10th percentile. To avoid overcorrection for
very low levels of inflammatory markers, only partici-
pants with CRP or ACT values above the 10th percentile
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(0.2 mg/L and 0.3 g/L for unlogged CRP and ACT
respectively) had their ferritin values subtracted from
observed values in Eqs. (1)–(3) below [10]. In the second
step, univariable linear regression models were applied
to the full dataset, with ferritin as the dependent vari-
able, to estimate regression coefficients for the crude as-
sociation between inflammatory marker level and ferritin
(β 1), and for the crude association between malaria and
ferritin (β 2), and multivariable linear regression was
applied to estimate adjusted regression coefficients for
associations between inflammatory marker level and fer-
ritin (β 3) and between malaria parasitemia and ferritin
(β 4). In the third step, the regression coefficients esti-
mated in step 2 were used to calculate adjusted ferritin
values using Eq. (1), (2), or (3). For the purposes of com-
parison, Eq. (1) was applied to adjust for the inflamma-
tory marker only, Eq. (2) for malaria parasitemia only,
and Eq. (3) for both inflammatory marker and malaria
parasitemia. Ferritin and inflammatory markers were ap-
plied in the equations after ln-transformation.
Ferritinadjusted1 ¼ Ferritinunadjusted
−β1 CRP or ACTobs−CRP or ACTrefð Þ
ð1Þ
Ferritinadjusted2 ¼ Ferritinunadjusted−β2malaria ð2Þ
Ferritinadjusted3 ¼ Ferritinunadjusted
−β3 CRP or ACTobs−CRP or ACTrefð Þ
−β4malaria
ð3Þ
where “obs” is the observed value and “ref” is the refer-
ence value.
We then defined ID using the regression-corrected
unlogged ferritin (i.e., adjusted for the effects of inflam-
mation and malaria) using the same thresholds that were
applied to the uncorrected ferritin levels in the WHO
recommendations (i.e., ferritin < 12 μg/L in children < 5
years or < 15 μg/L in children aged ≥ 5 years [7]) and
compared changes in prevalence of ID using McNemar’s
chi-square test of consistency. In further models, we
additionally corrected ferritin levels for age, sex, and
underweight. We also applied regression-correction for
inflammation and malaria to other markers of iron
status including sTfR, hepcidin, BIS, ferritin index, and
ZPP. We then tested the diagnostic utility of the uncor-
rected biomarkers in predicting ID regression-corrected
for inflammation and malaria as the “gold standard.” We
used receiver operating characteristics curve (ROC) ana-
lyses using regression-corrected ID as a binary classifier
for identifying the optimal cut-off values of the continu-
ous iron biomarkers. We defined the optimal cut-off
value as a point on the curve where the Youden index
(sensitivity + specificity − 1) is maximum [29].
Results
Characteristics of study participants
A total of 4853 children, 1484 Kenyan, 1374 Ugandan,
348 Burkinabe, 894 South African, and 753 Gambian,
aged between birth and 8 years were included in this
study. Table 1 shows the characteristics of study partici-
pants in the five African cohorts. The prevalence of
malaria parasitemia was highest in Kenya (21.9%) and
Table 1 Characteristics of study participants by cohort
Characteristic Kenya
n = 1484
Uganda
n = 1374
Burkina Faso
n = 348
South Africa
n = 894
The Gambia
n = 753
Pooled
n = 4853
Age in years, n/total (%)
< 1 321/1484 (21.6) 26/1374 (1.9) 21/348 (6.0) 475/894 (53.1) 0/753 (0.0) 843/4853 (17.4)
1–< 2 597/1484 (40.2) 459/1374 (33.4) 185/348 (53.2) 418/894 (46.8) 16/753 (2.1) 1675/4853 (34.5)
2–< 3 170/1484 (11.5) 622/1374 (45.3) 142/348 (40.8) 1/894 (0.1) 188/753 (25.0) 1123/4853 (23.1)
3–< 4 159/1484 (10.7) 176/1374 (12.8) 0 0 201/753 (26.7) 536/4853 (11.0)
4–8 237/1484 (16.0) 91/1374 (6.6) 0 0 348/753 (46.2) 676/4853 (13.9)
Age in years, median (IQR) 1.7 (1.1, 3.1) 2.0 (2.0, 3.0) 1.9 (1.6, 2.2) 1.0 (1.0, 1.0) 3.8 (2.9, 4.9) 2.0 (1.0, 3.0)
Gender: females, n/total (%) 726/1484 (48.9) 678/1374 (49.3) 173/348 (49.7) 449/894 (50.2) 331/753 (46.8) 2378/4853 (49.0)
Underweight*, n/total (%) 114/429 (26.6) 113/1368 (8.3) 60/327 (18.4) n/a 150/593 (25.3) 437/2717 (16.1)
Inflammation†, n/total (%) 392/1437 (27.3) 316/1337 (23.6) 112/330 (33.9) 157/894 (17.6) 112/753 (14.9) 1089/4751 (22.9)
Malaria‡, n/total (%) 262/1199 (21.9) 92/1353 (6.8) 66/321 (20.6) n/a 84/751 (11.2) 504/4518 (11.2)
Parasite density, median (IQR) 2295 (604, 6619) 122 (36, 350) 3714 (887, 18,103) n/a n/a 1386 (224, 5523)
n/a not available, IQR interquartile range
*Underweight was defined as weight-for-age z-score < − 2. Not measured in the South African cohort
†Inflammation was defined as C-reactive protein > 5 mg/L or α1-antichymotrypsin > 0.6 g/dL (in The Gambia)
‡Malaria was defined as P. falciparum parasitemia and parasite density as parasites/μL. Children in South Africa were not exposed to malaria and parasite density
data was not available for The Gambia. Pooled parasite density did not include South African or Gambian data
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Burkina Faso (20.6%) and lower in Uganda (6.8%). Simi-
larly, the prevalence of inflammation was high in
Burkina Faso (33.9%) and Kenya (27.3%), but lower in
South Africa (17.6%) and The Gambia (14.9%).
Distribution of iron status and anemia
Table 2 shows the prevalence of ID and anemia, and
concentrations of the individual iron biomarkers by
study cohort. Based on the WHO recommended defin-
ition, the prevalence of ID was highest in South African
children (41.9%) and lowest in The Gambia (21.7%) and
affected about a third of children in each of Kenya
(35.4%), Uganda (34.6%), and Burkina Faso (35.5%).
Anemia was present in 87.0% of children in Burkina
Faso, 70.0% in Kenya, 60.1% in The Gambia, and 49.7%
in Uganda.
Age, sex, and nutritional differences in iron status
Concentrations of ferritin, hepcidin, BIS, and TSAT de-
creased during the first year of life and increased
Table 2 Distribution of iron status and anemia by study cohort
Kenya Uganda Burkina Faso South Africa The Gambia Pooled*
Category n/
total
% 95%
CI
n/
total
% 95%
CI
n/
total
% 95%
CI
n/
total
% 95%
CI
n/
total
% 95%
CI
n/
total
% 95%
CI
Iron
deficiency†
499/
1408
35.4 32.9,
37.9
438/
1267
34.6 31.9,
37.2
115/
324
35.5 30.3,
40.7
375/
894
41.9 38.7,
45.2
163/
752
21.7 18.7,
24.6
1590/
4645
34.2 32.9,
35.6
Anemia‡ 609/
870
70.0 66.9,
73.1
652/
1312
49.7 47.0,
52.4
288/
331
87.0 83.4,
90.6
n/a n/a n/a 448/
746
60.1 56.5,
63.6
1997/
3259
61.3 59.6,
62.9
Iron
deficiency
anemia§
207/
833
24.8 21.9,
27.8
255/
1209
21.1 18.8,
19.8
96/
309
31.1 25.9,
36.3
n/a n/a n/a 123/
745
16.5 13.8,
19.2
681/
3096
22.0 20.5,
23.5
Biomarker n Mean 95%
CI
n Mean 95%
CI
n Mean 95%
CI
n Mean 95%
CI
n Mean 95%
CI
n Mean 95%
CI
Hemoglobin,
g/dL
870 10.2 10.1,
10.3
1312 9.1 9.0,
9.2
331 9.6 9.4,
9.7
n/a n/a n/a 746 10.7 10.6,
10.8
3259 10.5 10.5,
10.6
Ferritin, μg/L 1408 21.8 20.6,
23.1
1267 20.8 19.6,
22.0
324 22.2 19.7,
24.9
894 14.9 14.0,
15.9
752 25.1 23.6,
26.8
4645 20.5 19.9,
21.1
sTfR, mg/L 1467 17.9 17.5,
18.3
1343 6.7 6.5,
7.0
342 17.7 16.7,
18.7
893 11.2 10.9,
11.5
661 3.4 3.4,
3.5
4045 11.7 11.4,
11.9
Hepcidin, μg/
L
1373 5.8 5.4,
6.2
1333 6.8 6.4,
7.2
309 5.3 4.6,
6.3
878 7.7 7.1,
8.4
709 6.0 5.3,
6.7
4602 6.4 6.2,
6.6
BIS, mg/kg** 1393 −0.8 −1.0,
−0.5
1241 2.5 2.2,
2.8
322 −0.6 −1.1,
−0.1
893 −0.4 −0.7,
−0.2
660 5.7 5.4,
6.0
3849 0.4 0.2,
0.5
Ferritin
index††
1389 14.4 13.9,
14.9
1234 5.5 5.3,
5.8
322 13.9 12.8,
15.1
881 10.1 9.7,
10.6
660 2.6 2.5,
2.7
3826 9.7 9.5,
10.0
Serum iron,
μmol/L
1428 6.5 6.3,
6.7
n/a n/a n/a 337 6.0 5.7,
6.4
n/a n/a n/a 737 8.6 8.3,
8.9
1765 6.4 6.2,
6.6
Transferrin, g/
L
1409 2.8 2.7,
2.8
1333 2.8 2.6,
2.7
327 2.7 2.6,
2.8
894 2.7 2.7,
2.8
n/a n/a n/a 3963 2.8 2.7,
2.8
TSAT, %‡‡ 1386 9.4 9.0,
9.8
n/a n/a n/a 325 8.9 8.3,
9.7
n/a n/a n/a 734 12.8 12.3,
13.3
1711 9.3 9.0,
9.6
ZPP, μmol/
mol heme
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 751 85.9 82.4,
89.5
751 85.9 82.4,
89.5
MCV, fL 499 65.7 65.0,
66.5
1305 71.0 70.6,
71.5
n/a n/a n/a n/a n/a n/a 741 75.6 75.1,
76.1
2545 71.2 70.9,
71.6
n/a not available, BIS body iron store, sTfR soluble transferrin receptors, TSAT transferrin saturation, ZPP zinc protoporphyrin, MCV mean corpuscular volume
The mean values are geometric means except for BIS, transferrin, hemoglobin, and MCV which are arithmetic means
*Pooled values for sTfR, BIS, ferritin index, iron, transferrin, and TSAT, exclude The Gambia since markers were measured using different assays compared to the
other cohorts
†Iron deficiency defined using the WHO definition as ferritin < 12 μg/L or < 30 μg/L in presence of inflammation (C-reactive protein> 5 mg/L or α1-
antichymotrypsin > 0.6 g/dL) in children < 5 years or < 15 μg/L in children ≥ 5 years [8]
‡Anemia was defined as hemoglobin < 11 g/dL in children aged 0 to 5 years or hemoglobin < 11.5 g/dL in children above 5 years [27]. Hemoglobin measurements
unavailable in South Africa
§Iron deficiency anemia defined as iron deficiency and anemia [27]
**Body iron store was calculated using the ratio of soluble transferrin receptors and ferritin concentrations, −(log10((sTfR × 1000)/ferritin) − 2.8229)/0.1207 [24]
††Ferritin index was defined as sTfR/log10 ferritin [25]
‡‡TSAT was calculated as ((iron (μmol/L)/transferrin (g/L) × 25.1) × 100) except in The Gambia where it was calculated using iron and unsaturated iron binding
capacity [26]. Iron and TSAT missing in Uganda and South Africa and transferrin missing in The Gambia
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thereafter, indicating that ID is most prevalent at about
1 year of age (Fig. 1). Male infants were more iron
deficient than female infants for each of the different
measures of iron status, although hemoglobin concentra-
tions did not differ by sex. Sex-specific differences were
not observed beyond 3 years of age. The odds of malaria
parasitemia and underweight increased with age but did
not differ by sex, while underweight children were more
likely to have inflammation and malaria parasitemia
(Additional file 2: Table S2). Underweight was associated
with reduced hemoglobin levels, BIS, and higher sTfR
levels and ferritin index in models adjusted for age, sex,
study site, inflammation, and malaria parasitemia
(Additional file 4: Figure S1).
Associations between inflammation and malaria and iron
status
We then tested for associations between inflammation/
malaria parasitemia and individual markers of iron status
in multivariable models adjusted for age, sex, study site,
inflammation and malaria parasitemia (Fig. 2). Notably,
both inflammation and malaria parasitemia were inde-
pendently associated with substantially increased ferritin
levels. Inflammation was also independently associated
with increased BIS, hepcidin, and ZPP levels and
decreased hemoglobin, transferrin, ferritin index, and
serum iron levels (Fig. 2 and Additional file 4: Figure
S1). Malaria parasitemia was also independently associ-
ated with increased sTfR, hepcidin and ferritin index,
and decreased hemoglobin and transferrin after adjust-
ment for inflammation, age, sex, and study site. Overall,
TSAT was least affected by both inflammation and mal-
aria, particularly after additional adjustment for under-
weight (Additional file 4: Figure S1).
Estimating the regression-corrected prevalence of iron
deficiency
Ferritin levels were then adjusted for inflammation and
malaria using the regression-correction approach pro-
posed by BRINDA. Figure 3 shows the prevalence of ID
mapped on the African malaria map for the period
2010–2015 [30]. Excluding children with inflammation
resulted in a similar prevalence of ID as WHO-defined
ID. Adjustment of ferritin levels for inflammation alone
substantially increased the prevalence of ID compared to
adjustment for malaria alone, while adjustment for both
malaria and inflammation led to a small further increase
especially in Kenyan children who had the highest preva-
lence of malaria without inflammation (Fig. 3). Further
adjustments for age, sex, and underweight did not
Fig. 1 Geometric means for different iron biomarkers by age in years and sex. Orange indicates females and blue males. Error bars indicate 95%
confidence intervals. Star indicates Student’s t test p value < 0.05 for mean differences between sex. BIS, body iron stores; sTfR, soluble transferrin
receptor; TSAT, transferrin saturation
Muriuki et al. BMC Medicine           (2020) 18:31 Page 6 of 14
change the prevalence of ID (Additional file 5: Figure
S2). The pooled prevalence of ID after adjusting for both
inflammation and malaria was 52.0% and the absolute
increase in the prevalence of ID for each study site was
as follows: Burkina Faso, 27.0%; Kenya, 21.4%; Uganda,
20.0%; The Gambia, 16.8%; and South Africa, 8.5%
(Fig. 3). The gap between WHO-defined ID and regres-
sion correction was highest in cohorts that had the high-
est prevalence of malaria and inflammation (Kenya and
Burkina Faso) and lowest in malaria-free South Africa.
The prevalence of ID defined by other iron biomarkers
and by IDA similarly increased following regression-
correction for inflammation and malaria (Additional file 3:
Table S3).
Misclassification of iron-deficient children increases with
age, inflammation and malaria
The gap between the prevalence of WHO-defined ID
and regression-corrected ID increased with age, increas-
ing prevalence of malaria parasitemia (Fig. 4) and with
increasing CRP levels (Fig. 5a). Prevalence of regression-
corrected ID remained relatively constant over the
spectrum of CRP levels, while prevalence of WHO-
defined ID decreased linearly above the third decile of
CRP (0.4 mg/L), before adjustment for inflammation
(CRP > 5mg/L) (Fig. 5a). Malaria may also contribute to
underestimation of prevalence of ID. Malaria-endemic
countries had a higher percentage of children misclassi-
fied as iron replete (27.0% in Burkina Faso compared to
8.5% in South Africa; Fig. 3). The gap between WHO-
defined and regression-corrected prevalence of ID was
larger in children with malaria parasitemia compared to
those without, regardless of the presence of inflamma-
tion (Additional file 6: Figure S3). Children with malaria
also had higher ferritin concentrations at every decile of
CRP, compared to those without malaria (Fig. 5b).
Diagnostic utility of iron biomarkers in predicting
regression-corrected iron deficiency
Finally, we used the regression-corrected ID (corrected
for the effects of inflammation and malaria on ferritin
Fig. 2 Predictors of individual iron biomarkers. Effect size represents coefficient from multivariable linear regression model with the iron
biomarker as the outcome variable. Models were adjusted for age, sex, study site, inflammation, and malaria. Iron biomarkers were ln-transformed
except hemoglobin, transferrin, and BIS. Error bars indicate 95% confidence intervals and values indicate effect size (95% CI). Inflammation was
defined as C-reactive protein > 5mg/L or α1-antichymotrypsin > 0.6 g/dL (in The Gambia). Malaria was defined as P. falciparum parasitemia. BIS,
body iron stores; sTfR, soluble transferrin receptor; TSAT, transferrin saturation
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levels) as a gold standard to test the diagnostic utility of
various markers of iron status (Fig. 6). TSAT outper-
formed other markers of iron status. For TSAT, we ob-
served an area under curve (AUC) of 0.77 and an
optimal cut-off of 10.6, similar to the overall cut-off
(11.1) that was obtained from a meta-analysis of cohort-
specific optimal cut-offs (Fig. 6 and Additional file 7:
Figure S4). We then applied a rounded cut-off of TSAT
< 11% and obtained similar prevalence of ID as that ob-
tained using the regression-corrected definition of ID
(Fig. 3). TSAT < 11% also performed well across the
spectrum of CRP levels with only a modest increase in
prevalence of ID compared to regression-corrected ID
during inflammation (Fig. 5a). Other iron biomarkers
did not perform as well in predicting regression-
corrected ID. Hemoglobin concentrations had an AUC
Fig. 3 Prevalence of estimated iron deficiency across the study sites. The map shows the predicted posterior predictions of age-standardized P.
falciparum prevalence (PfPR2–10) as previously published by Snow et al. [30]. Map was reproduced with permission. Graph letter “a” indicates
prevalence of iron deficiency using the WHO definition, “b” excluding children with inflammation, “c” adjusting for malaria only, “d” adjusting for
inflammation only, “e” adjusting for both malaria and inflammation, and “f” using transferrin saturation cut-off of < 11%. Values indicate
prevalence. Malaria only indicates percentage of children with malaria parasitemia without inflammation, inflammation only as percentage with
inflammation and no parasitemia, and malaria and inflammation as percentage with both parasitemia and inflammation. Absolute increase in iron
deficiency was calculated as the difference between regression-corrected prevalence (corrected for both malaria and inflammation) and WHO-
defined prevalence. Error bars indicate 95% confidence intervals
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of 0.61 and an optimal cut-off of 11.25 g/dL with a sensi-
tivity of 75%, but low specificity of 42%, whilst sTfR con-
centrations had low sensitivity (43%) in predicting ID
corrected for inflammation and malaria (Fig. 6).
Discussion
Through this study, we have described iron status and
estimated the prevalence of ID in more than 4800 chil-
dren living across the African continent using a wide
range of iron biomarkers. Among infants, ID increased
from birth to approximately 1 year, and then decreased
with increasing age. Males were generally more iron de-
ficient than females up to 3 years of age. Underweight
children had increased ID and erythropoietic drive. In-
flammation and malaria parasitemia were associated
with independent and substantial increases in ferritin
concentrations and were also associated with other bio-
markers of iron status. We found that WHO-defined ID
underestimated the burden of ID in African children
compared to regression correction, which predicts fer-
ritin levels in the absence of inflammation and malaria.
Of the other iron markers that we tested, TSAT had the
best diagnostic properties when compared against the
gold standard of regression correction.
Age, sex, and being underweight were associated with
iron status in young African children. We found that
iron stores decreased rapidly during infancy and reached
a nadir at around 1 year of age, supporting the argument
that newborns have higher iron stores that are prenatally
accumulated but decrease with demand for iron during
rapid growth and low iron supply from breast milk and
complementary foods [31]. Iron status improved during
childhood, perhaps due to diversifying diets and redu-
cing growth rates post-infancy. Female infants were less
iron-deficient than males as observed in other studies
[31–34], and these gender-specific differences persisted
up to about 3 years of age. In agreement with previous
studies [35–37], underweight children had increased ID
and expanded erythropoiesis, suggesting that improving
the nutritional status of children may also help to
address ID and anemia.
Inflammation and malaria parasitemia substantially
altered measures of iron status in agreement with previ-
ous studies [10, 38, 39]. We found that both inflamma-
tion and malaria were independently associated with
increased levels of ferritin, thus, potentially leading to
children being misclassified as iron replete. We therefore
redefined ID by correcting ferritin levels for the effects
of inflammation and malaria using regression correction,
as previously proposed by BRINDA [10]. The strength of
this approach is that it accounts for continuous mea-
sures of inflammation as opposed to the arbitrary cut-off
points used by the WHO [7]. Compared to the inflam-
mation and malaria-corrected definition of ID, the WHO
definition substantially underestimated the prevalence of
ID among children living in sub-Saharan Africa. This
underestimate was particularly higher after adjusting for
inflammation only and additional regression correction
for malaria resulted in a more modest increase in the
Fig. 4 The burden of iron deficiency varies by age, sex, inflammation, and malaria parasitemia. Error bars indicate 95% confidence intervals for
prevalence of iron deficiency regression-corrected for inflammation and malaria. Darker colors indicate the WHO definition of iron deficiency
while lighter colors show the gap in the prevalence of iron deficiency between the two definitions (referred to as “hidden iron deficiency”). The
values in the bars indicate the percentage of children with iron deficiency unaccounted for by the WHO definition. Line plots indicate how the
prevalence of inflammation (black) and malaria (red) changed with age
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underestimate. The independent effect of inflammation
on ferritin levels was also greater than that of malaria.
Using a similar approach, Namaste et al. observed similar
absolute percentage increases (of up to 27%) in children
misclassified as iron replete using WHO-defined ID com-
pared to regression-corrected ID [10].
The underestimate of prevalence of ID by the WHO
was largest in cohorts that had a high burden of malaria
and other infections, for example, 27.0% and 21.4% of
Burkinabe and Kenyan children, respectively, were
misclassified as iron replete compared to 8.5% of South
African children. The unidentified burden of ID in-
creased with age in line with increasing prevalence of
malaria parasitemia, and we observed higher ferritin
levels among children with malaria parasitemia at every
decile of CRP. Malaria parasitemia also increased ferritin
levels independently of inflammation in multivariable
analyses. In agreement, a study in Burkinabe children
found that adjustment for asymptomatic malaria, in
addition to inflammation, led to a 11.9% absolute in-
crease in the prevalence of ID [40]. Taken together,
these findings indicate that both inflammation and mal-
aria parasitemia should be accounted for in population
estimates of prevalence of ID in African children.
We then evaluated the diagnostic utility of uncor-
rected iron biomarkers in predicting ID regression-
corrected for inflammation and malaria. A TSAT < 11%
best predicted regression-corrected ID indicating its po-
tential usefulness in estimating the prevalence of ID in
our study populations. TSAT is calculated from mea-
sured serum iron and either transferrin or UIBC, all of
which have standard assays that are easy and inexpensive
Fig. 5 Relationship between the estimated prevalence of iron deficiency and inflammation. a How the prevalence of estimates of iron deficiency
including WHO-defined ID, regression-corrected ID (corrected for inflammation and malaria), and TSAT < 11%, varied by deciles of C-reactive
protein (CRP) and b ferritin levels were higher in children with malaria parasitemia compared to those without parasitemia at every CRP decile.
Error bars indicate 95% confidence intervals. TSAT, transferrin saturation
Muriuki et al. BMC Medicine           (2020) 18:31 Page 10 of 14
to perform. TSAT< 11% performed well over a range of
CRP concentrations, in children with both malaria and
inflammation, and across populations. In support of our
findings, Aguilar et al. showed that TSAT had a high
sensitivity (81%) in predicting bone marrow ID in 180
anemic (hemoglobin < 11 g/dL) children in Mozambique
although specificity was low (40%) and an optimal cut-
off was not derived [38]. In contrast, another study in
Malawian children showed limited value of TSAT in diag-
nosing bone marrow iron stores in severely anemic chil-
dren (hemoglobin < 5 g/dL) [25]. Other iron markers did
not perform as well as TSAT in predicting corrected ID,
for example sTfR concentrations had very low sensitivity
(43%). The WHO recommends iron supplementation in
populations where the prevalence of anemia is ≥ 40% [41];
however, we found that hemoglobin concentrations had
very low specificity (42%) for predicting corrected ID
probably because of the multifactorial etiology of anemia
in African children [15]. Based on this guideline, all chil-
dren in our study populations would have received iron,
although approximately half were iron replete. Therefore,
TSAT may be a better marker than hemoglobin for deter-
mining the prevalence of ID in African children although
a more sensitive and specific marker is needed.
There were a number of important limitations of
our study. The cross-sectional nature of our data
limited us from analyzing longitudinal effects of in-
flammation, malaria, and nutritional status on iron
status. Moreover, we did not measure α-1-acid glyco-
protein (AGP), which has been shown to be a better
marker for adjusting for inflammation in regression-
correction analyses [10]. Nevertheless, unlike AGP,
CRP is more widely measured and international refer-
ence standards are available. We used ID regression-
corrected for inflammation and malaria as the gold
standard although this method is yet to be validated,
for example by either comparing prevalence estimates
of regression modeling before and during/after infec-
tions or with bone marrow ID. We used a ferritin-
based definition of ID since other iron biomarkers
have less standardized assays and less well-established
cut-offs for ID. Another limitation of our study was
that TSAT, the best performing marker in predicting
regression-corrected ID, was not available for Ugan-
dan and South African children, and although it out-
performed all other iron markers, it had an AUC of
only 0.77.
Conclusions
In this large-scale study including more than 4800
children in five countries across Africa, we explored a
wide range of iron biomarkers to more accurately
Fig. 6 Receiver operating characteristic curves of the utility of iron markers in predicting regression-corrected iron deficiency. The “gold standard”
was defined using the WHO definition adjusted for malaria and inflammation using regression correction. Green points indicate Youden’s optimal
cut-offs for each marker. Sensitivity and specificity are for the optimal cut-off. TSAT, transferrin saturation; sTfR, soluble transferrin receptor; AUC,
area under curve
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estimate prevalence of ID in countries with a high
burden of childhood infections including malaria.
There has been a long-standing concern regarding the
challenge of using iron biomarkers to accurately esti-
mate prevalence of ID in African populations [4]. In
this study, we found that after accounting for the ef-
fects of inflammation and malaria on ferritin levels
the prevalence of ID was substantially higher in Afri-
can children than currently estimated by the WHO.
Of the measured iron biomarkers, TSAT was the best
predictor of ID determined by the gold standard of
regression correction and may be useful in estimating
prevalence of ID to guide planning and implementa-
tion of interventions, since the regression-correction
approach would not be practical for programmatic
screening of children in routine care. Further research
is required for better interpretation of existing iron
biomarkers and to identify newer ones that are not
altered by malaria and other infections.
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